Pancreatic Cancer Research

ResearcherUniversity of Wisconsin SystemActive in the last 2 years

Daniel Erik Abbott

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5539-0734; OpenAlex author ID A5075432941. Sources: OpenAlex.

Their work

Papers
18 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers

Papers 18

  1. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  2. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2025.07.017↗
  3. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Co-author DOI 10.1016/j.prro.2025.01.011↗
  4. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  5. Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14347-w↗
  6. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  7. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  8. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  9. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.09.010↗
  10. National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04361-3↗
  11. Natural History and Treatment Trends in Pancreatic Cancer Subtypes. First author DOI 10.1007/s11605-019-04113-3↗
  12. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  13. Cohort Study of Overutilization of Preventive Screening for Patients With Pancreatic Cancer First author DOI 10.1097/mpa.0000000000001131↗
  14. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. First author DOI 10.1245/s10434-018-6650-z↗
  15. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and surviva… Co-author DOI 10.1007/s11605-013-2412-1↗
  16. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  17. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  18. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. First author DOI 10.1245/s10434-013-2889-6↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sharon Marie Weber · 11 shared papers, 2014–2025 · strength 1.20
  2. Nipun B. Merchant · 9 shared papers, 2014–2025 · strength 1.13
  3. Shishir Kumar Maithel · 9 shared papers, 2014–2025 · strength 1.13
  4. David A. Kooby · 8 shared papers, 2014–2025 · strength 0.93
  5. Syed Ameen Ahmad · 8 shared papers, 2013–2025 · strength 0.85
  6. Alexander A. Parikh · 6 shared papers, 2014–2025 · strength 0.78
  7. Syed Nabeel Zafar · 4 shared papers, 2024–2025 · strength 0.76
  8. Chet W. Hammill · 4 shared papers, 2022–2025 · strength 0.64
  9. Sean M. Ronnekleiv‐Kelly · 5 shared papers, 2018–2025 · strength 0.62
  10. Gregory C. Wilson · 5 shared papers, 2014–2024 · strength 0.62
  11. Jashodeep Datta · 4 shared papers, 2022–2025 · strength 0.62
  12. Hong Joo Kim · 4 shared papers, 2019–2024 · strength 0.51
  13. Rebecca Anne Snyder · 3 shared papers, 2023–2025 · strength 0.50
  14. Noelle K. LoConte · 3 shared papers, 2021–2025 · strength 0.49
  15. Robert C.G. Martin · 5 shared papers, 2014–2025 · strength 0.46
  16. Ifeanyichukwu Chinedu Ogobuiro · 3 shared papers, 2023–2024 · strength 0.45
  17. Alexander V. Fisher · 4 shared papers, 2018–2020 · strength 0.39
  18. Erin M. Dickey · 2 shared papers, 2024–2025 · strength 0.37
  19. Caitlin A. Hester · 2 shared papers, 2024–2025 · strength 0.37
  20. Jashodeep Datta · 2 shared papers, 2024–2025 · strength 0.37
  21. Mary P Martos · 2 shared papers, 2024–2025 · strength 0.37
  22. Peter J. Hosein · 2 shared papers, 2023–2025 · strength 0.35
  23. Emily R. Winslow · 5 shared papers, 2014–2019 · strength 0.33
  24. Charles Raben Scoggins · 4 shared papers, 2014–2025 · strength 0.33
  25. Michael Frederick Bassetti · 2 shared papers, 2021–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.